Latest news with #Werber


Business Insider
15-05-2025
- Business
- Business Insider
TD Cowen Remains a Buy on Nkarta (NKTX)
In a report released yesterday, Yaron Werber from TD Cowen maintained a Buy rating on Nkarta (NKTX – Research Report). The company's shares closed yesterday at $1.87. Confident Investing Starts Here: Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter According to TipRanks, Werber is a 4-star analyst with an average return of 5.3% and a 46.68% success rate. Werber covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Argenx Se, and Stoke Therapeutics. Currently, the analyst consensus on Nkarta is a Strong Buy with an average price target of $12.75. NKTX market cap is currently $143.3M and has a P/E ratio of -1.17.


Business Insider
13-05-2025
- Business
- Business Insider
TD Cowen Keeps Their Buy Rating on Jasper Therapeutics (JSPR)
In a report released yesterday, Yaron Werber from TD Cowen maintained a Buy rating on Jasper Therapeutics (JSPR – Research Report). The company's shares closed yesterday at $4.74. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. Werber covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Argenx Se, and Amgen. According to TipRanks, Werber has an average return of 5.2% and a 46.89% success rate on recommended stocks. Jasper Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $60.38. Based on Jasper Therapeutics' latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $1.17 million and a net profit of $46.95 million. In comparison, last year the company earned a revenue of $2.05 million and had a GAAP net loss of $16.58 million